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Abstract 
Background: We have previously demonstrated that reduced graphene oxide (rGO) administered intravenously in 
rats was detected inside the hippocampus after downregulation of the tight and adherens junction proteins of the 
blood–brain barrier. While down‑regulators of junctional proteins could be useful tools for drug delivery through the 
paracellular pathway, concerns over toxicity must be investigated before clinical application. Herein, our purpose was 
to trace whether the rGO inside the hippocampus triggered toxic alterations in this brain region and in target organs 
(blood, liver and kidney) of rats at various time points (15 min, 1, 3 h and 7 days).
Results: The assessed rGO‑treated rats (7 mg/kg) were clinically indistinguishable from controls at all the time points. 
Hematological, histopathological (neurons and astrocytes markers), biochemical (nephrotoxicity and hepatotoxicity 
assessment) and genotoxicological based tests showed that systemic rGO single injection seemed to produce mini‑
mal toxicological effects at the time points assessed. Relative to control, the only change was a decrease in the blood 
urea nitrogen level 3 h post‑treatment and increases in superoxide dismutase activity 1 h and 7 days post‑treatment. 
While no alteration in leukocyte parameters was detected between control and rGO‑treated animals, time‑dependent 
leukocytosis (rGO‑1 h versus rGO‑3 h) and leukopenia (rGO‑3 h versus rGO‑7 days) was observed intra‑treated groups. 
Nevertheless, no inflammatory response was induced in serum and hippocampus at any time.
Conclusions: The toxic effects seemed to be peripheral and transitory in the short‑term analysis after systemic 
administration of rGO. The effects were self‑limited and non‑significant even at 7 days post‑rGO administration.
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Background
Graphene is a single layer of densely packed, regular 
sp2-bonded carbon atoms arranged in a hexagonally two-
dimensional structure [1]. Graphene and derivatives, 
such as graphene oxide (GO) and reduced graphene 
oxide (rGO), have attracted significant interest in many 
technological fields due to their unique electronic, opti-
cal, magnetic, thermal and mechanical properties. These 
properties have led to broad-spectrum material and 
biomedical applications, such as the use in biosensors, 
optical imaging, drug/gene delivery, photothermal ther-
apy and tissue engineering [2–6].
With regard to rGO, the results of toxicological stud-
ies appear to be inconclusive, as there is no broad con-
sensus on whether it is non-toxic and biocompatible 
[7–9]. These discrepancies have been attributed to many 
aspects related to the physicochemical properties (e.g., 
size, shape, surface chemistry, composition and aggre-
gation) of the nanomaterial [10], and the experimental 
design used [11].
In our pioneer work with rGO, we demonstrated that 
rGO administered intravenously (i.v) through the tail 
vein of rats was further detected inside the brain tissue 
and particularly concentrated in the thalamus and hip-
pocampus. We also found that Evans blue vital stain 
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infusion in rGO-treated rats escaped from the peripheral 
circulation and entered the brain, indicating blood-brain 
barrier (BBB) disruption. With focus in hippocampus, 
we found that the possible entrance door of rGO into 
this brain region might have been in the course of a tran-
sient downregulation of the junctional proteins of the 
capillary endothelium [12]. The elaborate organization 
of such proteins maintains tightly attached to each other 
the capillary endothelial cells preventing the passage of 
substances through the paracellular pathway [13]. Such 
temporary decrease of the paracellular tightness of the 
BBB, the presence of rGO inside the hippocampus and 
the unnoticeable negative effect to animals’ exploratory 
behavior was predictor of a positive outcome in studies 
related to the toxicity of rGO.
In general, the toxicity of nanomaterials has been 
evaluated through their capacity to interfere in cellu-
lar mechanisms related to allergy, fibrosis, organ failure, 
hemocompatibility, neurotoxicity, nephrotoxicity and 
hepatotoxicity [14].
In the present study, we used the same experimental 
design and animal model as in our previous study [12] to 
delineate a possible toxic profile of rGO. The focus of the 
study was the hippocampus, and the peripheral organs 
(blood, kidney and liver) recognized as impact organs 
against xenobiotics. The purpose of the present study was 
to expand the understanding of rGO-tissue interactions 
in vivo, promoting safe and responsible use of rGO-based 
technology for future therapeutic application studies.
Results and discussion
rGO did not induce clinical signs of neurotoxicity in rats
A clinical evaluation was performed in rats before and 
after rGO injection in search of possible evidence of side-
effects. Signs of tremor, piloerection, salivation, lacrima-
tion, dyspnea, convulsions, hindlimb and forelimb grip 
strength, or other motor abnormalities were examined 
as symptoms of neurotoxic insult [15]. Animals from 
the rGO-treated groups did not show any of the signs 
described in Table 1 at any of the time-frame of the study 
(15 min, 1, 3 h and 7 days). The liveliness and exploratory 
behavior, typical of healthy rats, was equally observed in 
the control and rGO-treated animals.
Differently, Zhang and collaborators [16] reported that 
rGO nanosheets orally administered to mice caused a 
short-term decrease in locomotor activity and neuro-
muscular coordination. Other signs such anxiety-like, 
exploratory, or spatial learning and memory behaviors 
remained unnoticed. We suggest that the differences in 
relation to our findings are attributed do some aspects: 
(1) while we administered a single i.v. dose (7 mg/kg) to 
rats, Zhang et  al. used high-dose (60  mg/kg adminis-
tered orally for five consecutive days) to mice; (2) while 
our rGO was 342  ±  23.5  nm in size, theirs were small 
(87.97  ±  30.83) and large-sized (472.08  ±  249.17  nm). 
We conclude that experimental design, animal model 
and physicochemical characteristics of the nanoma-
terials have a key role in the development of toxic 
manifestations.
rGO did not alter the neuronal viability marker and did not 
promote astrogliosis in the hippocampus of rats
Since rGO i.v. administration was shown to downregulate 
the junctional proteins responsible for the tight apposi-
tion of the endothelial cells of the BBB and was detected 
inside the brain [12], the next step was to investigate pos-
sible neurotoxic effects in the tissue. Firstly, we performed 
a histological evaluation of hematoxylin-eosin-stained 
hippocampus in search of tissue damage, inflammation 
or necrosis. Secondly, we evaluated the nuclear antigen 
protein (NeuN)—a marker of neuron maturation and 
viability—and the glial fibrillary acidic protein (GFAP), a 
protein of the intermediate filament of astrocytes and a 
marker of reactivity by triggering mechanical strength of 
the glia cytoskeleton in response to noxious stimuli to the 
brain. The relevancy of analyzing neurons and astrocytes 
rely on the fact that together with capillary endothelial 
cells and pericytes they constitute the neurovascular unit, 
a concept highlighting the functional cell–cell interactions 
which support BBB function [17, 18].
The histological analysis of the hippocampus of treated 
animals showed that morphologically it did not differ 
Table 1 Summary of clinical signs and behavioral response destined to evaluate neurotoxicity before and after rGO i.v 
administration (7 mg/kg)
All the parameters evaluated in rGO-treated rats showed no discrepancy relative to the observed in rats treated with vehicle (control)
n = 3–5 per time of sampling; n = 5 control group
Autonomic nervous system Peripheral nervous system (neuromuscular) Behavioral (activity) Central nervous system (excitability)
Lacrimation Righting reflex Motor activity Clonic movements
Salivation Hindlimb grip strength Home cage posture Tonic movements
Excretion Forelimb grip strength Rearing
Piloerection
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from that observed in the control group regardless of the 
time following administration of rGO (Fig. 1a, b). Consid-
ering the neurons, NeuN immunolabeling showed that the 
nucleus of pyramidal neurons of the Cornu ammonis (CA) 
subfields (Fig. 1c, d) and the granule neurons of the den-
tate gyrus (not shown) of the hippocampus were typically 
reactive, not differing among treated and control animals. 
However, the NeuN content evaluated by immunoblot-
ting in the hippocampal homogenates of rGO-treated ani-
mals (Fig. 1g) showed an immediate but episodic rise of 
37 % (p < 0.05) in the protein expression level at 15 min. 
Thereafter, at 1, 3 h and 7 days NeuN immunolabeling and 
protein content returned to control basal levels. It is prob-
able that a feeble mechanism of neurotoxicity had been 
immediately triggered after rGO injection, but it did not 
result in major change in the expression of NeuN. The 
increases in NeuN expression suggests enhanced or at 
least maintained neuronal viability. In addition, it means 
hippocampus plasticity, in which transitory migration of 
neurons may occur in response to local insult, resulting in 
fleeting increases of NeuN level.
With regard to the hippocampal astrocytes, a possible 
reaction against rGO would be by hypertrophy of the 
cytoskeleton and/or cell hyperplasia, a process known 
as reactive gliosis or astrogliosis [19]. Figure  1 illus-
trates GFAP labeling in the hippocampal CA1 region 
of a rat treated with a vehicle (panel E) and 15 min after 
rGO administration (panel F). Regardless of time post-
rGO exposure, we observed soma and processes of the 
hippocampal astrocytes GFAP-positive, similar to that 
observed in control group. Likewise, the other hippocam-
pal subfields, CA2, CA3, and dentate gyrus showed no 
difference between rGO-treated and control animals (data 
not shown). Quantitative analysis of the hippocampal 
homogenate by western blotting showed that treatment 
with rGO resulted in no significant alterations in GFAP 
levels over time, revealing absence of reactive astrogliosis 
(Fig.  1h). This indicates that rGO systemic injection did 
not induce substantial reactive response in astrocytes.
rGO did not alter hematological parameters relative 
to control
In order to retain their engineered functions in  vivo, 
nanomaterials used for biomedical applications should be 
compatible with blood [8]. No significant changes in any 
of the hematological parameters were observed in com-
parison with the control group. However, intra-group 
analysis revealed differences in the number of white 
blood cells (WBC) (Table 2). The rGO-3 h group showed 
a 59  % increase in the number of WBC relative to the 
rGO-15  min group, thus characterizing a time-depend-
ent intra-rGO group leukocytosis (p  <  0.05). This effect 
was transient as it was followed by a 115  % decrease 
when comparing the rGO-3 h group with the rGO-7 day 
group, hence characterizing an intra-rGO group time-
dependent leukopenia (p  <  0.01). All the other parame-
ters showed steady figures over time with values at 7 days 
practically the same as those exhibited by control group.
It has been demonstrated that graphene-based nano-
materials were compatible with blood and did not cause 
hemolysis, platelet activation and changes in coagula-
tion or abnormalities in hematological parameters [20]. 
In contrast, Singh et  al. [21] reported that intravenous 
administration of GO (250  μg/kg body weight) caused 
strong platelet aggregation and extensive thromboembo-
lism in mice. Interestingly, much less platelet aggregation 
occurred with rGO, which may be correlated to differ-
ence in surface charge distribution from GO as the same 
concentration and animal model were used.
In rodents, several types of stimulus such as exercise, 
environmental factors, nutrition (food and water) and 
inflammatory response [22], can influence WBC levels 
[23]. In comparison with the control group, our results 
showed that rGO-treated animals did not alter signifi-
cantly leukocytes number. The variability seen among 
rGO groups on WBC counts might be considered rather 
moderate, as the values observed here are still within the 
reference ranges found in rats [23, 24].
To confirm that the time-dependent leukocytosis (from 
15 min to 3 h) did not represent an inflammatory reac-
tion in response to rGO we assessed the levels of inter-
leukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) 
pro-inflammatory cytokines in serum (ELISA assay) and 
the expression of TNF-α and interferon-γ (IFN-γ) in the 
hippocampal homogenates (WB data). IL-6 and TNF-α 
was undetectable in the serum of rGO-treated rats. All 
samples measured less than the lowest rat standard levels, 
62.5 pg/mL for IL-6 and 125 pg/ml for TNF-α. Likewise, 
(See figure on next page.) 
Fig. 1 Light micrographs of CA1 hippocampal subfield of rats 1 h after i.v. injection of vehicle (a) and 15 min after i.v. injection of rGO (b), 
Hematoxylin‑eosin. Insets show greater magnification of hippocampal pyramidal neurons with preserved euchromatic nuclei and visible nucleoli 
both in control and treated samples. Or stratum oriens; Py stratum pyramidale; Rad stratum radiatum. NeuN and GFAP labeling of 1 h‑control rats (c, 
e) and 15 min after i.v. injection of rGO (d, f), respectively. Western blot signals of NeuN (g) and GFAP (h) after administration of rGO (7 mg/kg) in 
hippocampal tissue lysates were quantified densitometrically and normalized to an internal standard protein (β‑actin). The results were shown as a 
percentage of control (100 %), and represent mean ± SEM (n = 5 rats/interval). *p < 0.05 indicates significant difference relative to control. One‑way 
ANOVA, Bonferroni post hoc test; Bars 100 µm (a–f), 50 µm (insets)
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no significant change was observed in the expression 
of either inflammatory marker over time (Fig.  2). Based 
on these results and in the absence of inflammatory cell 
infiltration (Fig.  1b), it appears that the increase in the 
number of WBC cells intra-rGO-treated groups cannot 
be associated to any inflammatory process.
Morphological and functional evaluations show minimal 
effects of rGO in liver and kidney
To better analyze the safety of using rGO, hepatotoxicity and 
nephrotoxicity were evaluated to determine whether or not 
rGO caused alterations in liver and kidney morphology and 
function. These organs are important components for detox-
ification and clearance of nanoparticles, respectively [25].
rGO systemic administration did not produce detect-
able changes in the lobular architecture of the liver, which 
was preserved and remained normal in all treated rats at 
the studied time-frame (Fig. 3a, b) even 7 days after rGO 
administration (data not shown). Likewise, no immuno-
positive apoptotic cells were detected (Fig. 3c, d). Typically, 
collagen fiber density was only visible in the hepatic por-
tal venous system and this was unchanged in control and 
rGO-treated tissue (insets Fig. 3e, f ); equally no alterations 
in the connective tissue were detectable in the peri-sinu-
soidal space in rGO-treated samples stained with Masson’s 
trichrome (Fig. 3f) compared to control (Fig. 3e). The data 
suggest that in these experimental conditions there were 
absence of hepatocytes apoptosis and tissue fibrosis.
Table 2 rGO effects on hematological parameters of male Wistar rats
The same symbol in each column indicates a significant difference between groups
One-way ANOVA, Bonferroni post hoc test; data were shown as mean ± SEM, n = 3–5 in each group
RBC red blood cell; Hb hemoglobin; Hct hematocrit; MCV mean corpuscular volume; MCH mean corpuscular hemoglobin; MCHC mean corpuscular hemoglobin 
concentration; PLT platelet; WBC white blood cell
*p < 0.05; #p < 0.01
Group Unit Control rGO 15 min rGO 1 h rGO 3 h rGO 7 days
RBC 106/μl 7.32 ± 0.09 7.16 ± 0.17 7.45 ± 0.02 7.27 ± 0.11 7.48 ± 0.04
Hb g/dl 14.27 ± 0.24 13.73 ± 0.12 14.37 ± 0.14 14.00 ± 0.24 14.32 ± 0.37
Hct % 46.87 ± 0.52 46.13 ± 0.88 48.83 ± 0.57 47.58 ± 0.24 47.70 ± 0.40
MCV fl 64.00 ± 0.60 64.60 ± 0.23 65.53 ± 1.02 65.44 ± 0.66 63.44 ± 0.49
MCH pg 19.03 ± 0.23 19.03 ± 0.32 19.27 ± 0.24 19.22 ± 0.21 19.24 ± 0.26
MCHC g/dl 29.80 ± 0.40 29.57 ± 0.40 29.43 ± 0.08 29.42 ± 0.42 30.38 ± 0.33
PLT 103/μl 638.3 ± 5.84 650.0 ± 6.92 649.0 ± 10.69 624.2 ± 25.81 636.2 ± 59.19
WBC 103/μl 7.63 ± 0.60 6.80 ± 1.41* 7.10 ± 0.30 10.83 ± 0.55*,# 5.03 ± 0.56#
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Fig. 2 Expression of TNF‑α (a) and IFN‑γ (b) in hippocampal homogenates after rGO i.v. administration (7 mg/kg). Western blot signals were den‑
sitometrically quantified, normalized to an internal standard (β‑actin) and the results expressed as percentage of control (100 %). One‑way ANOVA, 
Bonferroni post hoc test; data were shown as mean ±SEM; n = 5/group
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With regard to kidneys, the tubular, glomerular tufts 
and renal corpuscles and interstitium of rGO-treated 
rats were normal in appearance and did not differ from 
control (Fig.  4a, b). Caspase-9 immunostaining allowed 
identifying dispersed nephron segments with apop-
totic cells (brown-labeled cells) both in control (Fig. 4c) 
and rGO-treated rats (Fig. 4d). As is common, the renal 
parenchyma shows minimal connective tissue support 
in physiologic condition (Fig. 4e), and no alteration was 
apparent in rGO-treated animals (Fig. 4h).
Additionally, we evaluated the levels of aminotrans-
ferases, alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), in serum, as in drug safety stud-
ies these enzymes are key indicators of drug-induced 
liver toxicity involving laboratory animals and patients. 
These enzymes are abundant within hepatocytes and 
catalyze the formation of glutamate through the transfer 
of an amino group [26]. Thus, increased levels of these 
enzymes in the blood are one of the first laboratory signs 
of hepatic dysfunction. As shown in Table 3, no alteration 
Fig. 3 Light micrographs of parts of hepatic lobules at 1 h‑control (a, c, e), rGO‑15 min (b) and 7 days—rGO treated rats (d, f). Representative pho‑
tomicrographs of the hepatic parenchyma stained with Hematoxylin‑eosin (a, b); treated for immunostaining of anti‑caspase 9 (c, d) and stained 
with Masson’s trichrome staining for detecting collagen type 1 in normal (e) and rGO‑treated (f) tissue. Insets depict collagen fibers around the 
blood vessels. pv portal vein; cv central vein. Bars 100 µm
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was found in the enzyme levels in comparison with con-
trol over the time-frame scheduled.
Next, renal glomerular function was estimated by 
assessing creatinine and blood urea nitrogen (BUN) 
levels, two markers of renal function [27]. We did not 
observe alterations in creatinine levels; but found a tran-
sitory and unexpected 37 % decrease in BUN levels at 3 h 
in the rGO-treated animals, compared with the control 
group (p  <  0.05, Table  3). Decreases in BUN level were 
also found as time post-rGO exposure advanced: 27  % 
(p < 0.05) decrease in rGO-15 min versus rGO-1 h and 
63 % (p < 0.001) decrease in rGO-15 min versus rGO-3 h. 
One week after rGO treatment, BUN levels had returned 
to the control rate, which may indicate that in case of 
hepatotoxicity or nephrotoxicity occurrence they were 
short-lived. Moreover, the histopathological examination 
of kidney and liver morphology showed none abnormal-
ity in the rGO-treated group.
Fig. 4 Renal cortical sections stained with Hematoxylin‑eosin (a, b), immunostained for caspase 9 (c, d) and stained with Masson’s trichrome (e, f). 
The sections were obtained from vehicle‑treated (control—1 h) rats (a, c, e) and 15 min (b) and 7 days (d, f) after intravenous injection of rGO. Note 
that there is no change between the aspect of control and rGO‑treated sections in each of the staining assessments. The widening of the tubular 
lumen and capsular space was observed in control and rGO samples due to perfusion fixation. Insets depict that collagen density (just in large 
blood veins of renal stroma) was the same for control and rats treated with rGO. 1 Renal glomeruli; 2 proximal tubule; 3 distal tubule; 4 collecting 
tubule; * Bowman’s space of the renal corpuscle. Arrows point to the immuno‑positive apoptotic cells (brown). Bars 100 µm for all panels
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BUN analysis also provides information about hepatic 
functioning, as the nitrogen from ammonia produced 
by the liver will participate in urea formation which will 
be further excreted by the kidney as a waste metabolism 
product. Increases in BUN levels indicate that either the 
kidney or the liver may not be functioning properly. In 
humans, low levels of BUN have been observed in several 
morbid conditions such as those caused by trauma, sur-
gery, malnutrition and opioids and anabolic steroid use 
and fluid excess [27, 28], whereas low levels are not com-
mon and not usually reported in animals.
Evaluation of oxidative stress and DNA damage generated 
by rGO
As one of the most important mechanisms explored in 
graphene-based nanomaterials studies, oxidative stress 
has been the focus of toxicological studies [9, 29]. It is 
well known that the generation and elimination of reac-
tive oxygen species (ROS) is dynamically balanced inside 
cells, and severe increases in ROS levels may induce 
genotoxicity, protein inactivation, lipid peroxidation, 
mitochondrial dysfunction, and eventually cell death by 
apoptosis or necrosis [30–32].
Herein, the influence of rGO in the response of bio-
markers of oxidative stress was assessed through the 
expression and activities of the antioxidant enzymes 
superoxide dismutase (SOD) and catalase (CAT), known 
to be involved in the detoxification of hydrogen peroxide 
(H2O2). SOD converts the superoxide radical into H2O2 
while CAT converts H2O2 into water [33]. We further 
evaluated the thiobarbituric acid reactive substances 
(TBARS), as a marker of lipid peroxidation.
rGO systemic single injection induced upregulation in 
serum SOD activity, while CAT activity was unaffected. 
Likewise, no significant differences were detected in 
serum TBARS levels between rGO-treated and control 
animals, indicating that lipid peroxidation was unaltered 
(Table 4). SOD activity rose progressively from 15 min up 
to 7  days. Relative to control, SOD activity increased at 
1 h (54 %, p < 0.05) and at 7 days (69 %, p < 0.01), after 
the injection of rGO. Intra-group analysis revealed a sig-
nificant increase (57 %, p < 0.01) in rGO-7 days relative to 
rGO-15 min.
Western blot analyses did not show significant differ-
ence in SOD-1 or CAT protein expression over the time 
course analyzed (Fig. 5a, b), suggesting that rGO did not 
alter transduction signal.
Therefore, we decided to investigate whether the gen-
eration of oxidant compounds by systemic rGO injec-
tion, as inferred by the increase in the SOD activity, had 
induced genotoxicity and cell death under the influence 
of rGO.
As shown in Table 5, rGO did not induce cytogenetic 
damage. There was no difference in the frequency of 
micronucleated erythrocytes in the circulating blood of 
control rats and in the blood collected from rats 7 days 
after a single i.v. injection of rGO. In human glioblastoma 
cell lines U87 and U118, GO and rGO decreased cell 
Table 3 Effects of rGO on biochemical parameters of hepatic and renal function
Values are mean ± SEM of 3–5 animals in each group. The same symbol in each column indicates a significant difference between groups
One-way ANOVA, Bonferroni post hoc test
ALT alanine aminotransferase; AST aspartate aminotransferase; BUN blood urea nitrogen
#,* p < 0.05; ∇p < 0.001
Unit Control rGO 15 min rGO 1 h rGO 3 h rGO 7 days
ALT U/L 44 ± 3.5 56 ± 3.9 54 ± 0.5 44 ± 3.2 48 ± 2.3
AST U/L 148 ± 9.9 177 ± 8.4 152 ± 7.5 156 ± 9.5 151 ± 6.6
BUN mg/dL 48 ± 2.2# 57 ± 3.2*,∇ 45 ± 3.3* 35 ± 0.7#,∇ 48 ± 1.8
Creatinine mg/dL 0.31 ± 0.003 0.35 ± 0.017 0.29 ± 0.021 0.30 ± 0.017 0.34 ± 0.020
Table 4 rGO effects on serum SOD, catalase and TBARS levels in male Wistar rats
Values are mean ± SEM of 3–4 animals in each group. The same symbol in each column indicates a significant difference between groups
One-way ANOVA, Bonferroni post hoc test
SOD superoxide dismutase; CAT catalase; TBARS thiobarbituric acid reactive substances
#p < 0.05; *,∇p < 0.01
Unit Control rGO 15 min rGO 1 h rGO 3 h rGO 7 days
SOD U/ml 13 ± 0.4#,* 14 ± 0.8∇ 20 ± 0.6# 20 ± 2.6 22 ± 1.1*,∇
CAT nmol/min/ml 129 ± 2.8 151 ± 12.5 112 ± 28.8 88 ± 17.3 120 ± 6.1
TBARS nmol/ml 7.6 ± 1.0 7.7 ± 1.7 7.4 ± 2.4 6.2 ± 0.3 5.7 ± 1.3
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viability and proliferation, however rGO was more toxic 
than GO. In rGO-treated U87 tumors the expression of 
caspase-3 was 96 % higher compared with controls [34]. 
Herein, no substantial differences were observed in cas-
pase 3 levels in the hippocampal homogenates between 
controls and animals treated with rGO.
We suggest that induction of oxidative stress by rGO 
was moderate and that the reductive defense system pro-
vided by SOD activity was triggered to restore the oxi-
dant/antioxidant balance.
Conclusions
Overall, the intravenous administration of rGO (7 mg/kg 
single dose) led to minor signs of toxicity in the blood, 
liver and kidney after 7  days with no sign of inflamma-
tion process in course. These effects were transitory and 
did not lead to permanent damage. Also, no perceptible 
change was observed in hippocampal neurons or astro-
cytes response, despite a previous study demonstrating 
BBB disruption and detecting rGO distribution inside 
this brain region [12]. The activity of control and rGO-
treated animals in their cages was the same, with no 
apparent clinical signs of toxic manifestation. In conclu-
sion, the data suggests that systemic administration offers 
no significant health risk for rats in these experimental 
conditions. Nevertheless, it seems clear that the interac-
tions between graphene-based materials with biological 
systems are highly dependent on the experimental design 
used and the physicochemical properties of the nano-
material. For the development of graphene-based nano-
medicine, it is important the development of systematic 
toxicological investigations to fully understand the bio-
logical effects and address safety concerns before the 
practical application of any graphene-based materials in 
the clinic. The present study provides a basis for further 
toxicological studies of rGO after long-term in vivo expo-
sure, and is an incentive for studies of the mechanisms 
underlying rGO and cell/biological system interaction.
Methods
Preparation and characterization of rGO
The processing for rGO was the same described before 
to maintain identical properties as the used in our previ-
ous study [12]. Briefly, rGO was prepared after catalytic 
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Fig. 5 Expression of SOD‑1 (a) and catalase (b) in hippocampal homogenates after rGO i.v. administration (7 mg/kg). Western blot signals were 
densitometrically quantified, normalized to an internal standard (β‑actin) and the results expressed as percentage of control (100 %). One‑way 
ANOVA, Bonferroni post hoc test; data were shown as mean ± SEM; n = 5 in each group
Table 5 Effect of rGO on the frequency of polychromatic erythrocytes with micronuclei in the peripheral blood and cas-
pase-3 expression
Protein expression levels were expressed as percentage of control (100 %) after normalization to an internal standard (β-actin). One-way ANOVA, Bonferroni post hoc 
test; data were shown as mean ± SEM; n = 5 in each group
NA not assessed
Control rGO 15 min rGO 1 h rGO 3 h rGO 7 days
Micronucleus index 0.68 ± 0.13 NA NA NA 0.64 ± 0.19
Caspase 3 92.46 ± 2.88 101.3 ± 11.66 91.71 ± 8.00 89.05 ± 15.99 95.97 ± 14.46
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conversion using a copper substratum to which was 
added 1 ml of polyaniline diluted in dimethylformamide 
(Synth, São Paulo, SP, Brazil), after which it was allowed 
drying for 2 h at room temperature. After, 0.2 ml of nickel 
nitrate dissolved in pure acetone (Synth) was added to 
the preparation which was subsequently placed within a 
chemical vapor deposition reactor assisted by a hot fila-
ment. The hydrocarbons used as a carbon source were 
camphor and acetone. Raman spectrometry (Renishaw, 
Wotton-under-Edge, UK) for molecular structure charac-
terization, Field Emission Scanning Electron Microscopy 
(JEOl JSM-6330F, Japan) for morphological description 
and dynamic light scattering for measurement of size, 
zeta potential and polydispersity index (PDI) (ZetaPALS 
Zeta Potential Analyzer, Brookhaven Instruments, NY, 
USA) confirmed that rGO characteristics were the same 
exhibited in our previous study (sized 342  ±  23.5  nm, 
−25 ± 0.18 mV zeta potential, 0.56 ± 0.03 PDI).
In this work, we performed additional information 
about physicochemical properties of rGO. The average 
thickness of the rGO sheet measured by Field Emission 
Scanning Electron Microscope (FE-SEM) (Zeiss Supra 
55 VP-SEM) was estimated to be ∼5 nm (Fig. 6a). rGO 
showed remarkable stability in water and different physi-
ological solutions including 0.9 % saline solution, Dulbec-
co’s Modified Eagle Medium (DMEM), and bovine serum 
albumin (BSA) (Fig. 6b).
Animal treatment
Experiments were carried out in accordance with the 
Brazilian Society of Laboratory Animal Science guide-
lines and approved by the Institutional Committee for 
Ethics in Animal Use (CEUA/IB/UNICAMP, protocol 
n. 2884-1). The experimental animals used in our previ-
ous study [12] were the same used in the present one. We 
used healthy male Wistar rats (average weight 180–220 g; 
6  weeks old; n =  3–5 in each group) for evaluating the 
nanotoxicity of rGO.
Animals (Rattus norvegicus) received a single tail 
vein injection of rGO (7  mg/kg dose; concentration of 
1  mg/ml) [35], while the control group was given the 
same volume of vehicle (sterile distilled water). Fif-
teen minutes, 1, 3  h and 7  days after the i.v. adminis-
tration of rGO, the animals were euthanized by carbon 
dioxide (CO2) inhalation (western blotting analysis) or 
anesthetics overdose [3:1 mixture of ketamine chloride 
(Dopalen®, 100  mg/kg body weight, Fortvale, Valinhos, 
SP, Brazil) and xylazine chloride (Anasedan®, 10  mg/kg 
body weight, Fortvale)] and the target samples (blood, 
brain, liver and kidneys) immediately removed. Animals 
of the control group received an i.v. injection of vehicle 
and were euthanized 1 h later. A single control group was 
used as preliminary experiments showed no time differ-
ence relative to data.
Neurotoxicity evaluation
The clinical and behavioral signs were evaluated in con-
trol and rGO-treated rats using the functional observa-
tion battery described by Moser [36]. All observations 
were performed by the same trained observer who was 
unaware of treatments.
Systemic toxicological profile of rGO
Fifteen minutes, 1, 3  h and 7  days after treatment with 
rGO, the animals were deeply anesthetized and blood 
samples were collected via cardiac puncture immediately 
prior to transcardial perfusion and divided into two parts, 
(1) collected into EDTA-containing tubes and used for 
hematological and genotoxicity studies, and (2) collected 
into serum separator gel tubes and used for enzyme-
linked immunosorbent assay (ELISA), biochemical stud-
ies and analysis of the activity of antioxidant enzymes.
Fig. 6 FE‑SEM image of rGO sheet with a thickness of ~5 nm (a). rGO suspension in water, 0.9 % saline, DMEM cell medium and BSA displaying 
great stability (b)
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Hematological studies
Hematological parameters—numbers of red blood cells, 
hemoglobin, hematocrit, mean cell volume, mean cor-
puscular hemoglobin, mean corpuscular hemoglobin 
concentration, platelet and white blood cell count—were 
determined using an automated hematology analyzer 
(Coulter T540 hematology system; Fullerton, CA, USA).
ELISA
Blood samples were centrifuged for 10 min at 3000 rpm 
and the resulting serum was stored at −80  °C. The 
cytokines IL-6 and of TNF-α were determined using Rat 
DuoSet ELISA kits (R&D Systems; Minneapolis, MN, 
USA) following the instructions supplied by the manu-
facturer. The limit of detection of these kits was 125 pg/
ml for IL-6 and 62.5 pg/ml for TNF-α.
Biochemical parameters
The blood samples for biochemical analyses were centri-
fuged at 3000  rpm for 10  min, the serum aspirated and 
analyzed by an automated analyzer Cobas® 6000 (Roche 
Diagnostics, Mannheim, Germany) for the determination 
of AST and ALT activities and the concentration of BUN 
and creatinine.
Antioxidant enzymes activity and lipid peroxidation 
evaluation
Lipid peroxidation was evaluated using TBARS tech-
nique described by Ohkawa, Ohishi, and Yagi [37] and 
adapted by Batista et al. [38], in which malondialdehyde 
and the final products of lipid peroxidation react with 
thiobarbituric acid, forming a pink-colored complex.
The enzyme antioxidant systems (SOD and CAT) in 
the serum samples were measured using colorimetric 
methods. The SOD activity in serum was obtained after 
reaction with hypoxanthine, nitroblue tetrazolium and 
0.07 U of xanthine oxidase as described in detail before 
[38].
The CAT activity method was carried out based on the 
reaction of the enzyme with methanol and H2O2. Purpald 
(4-amino-3-hydrazino-5-mercapto-1,2,4-triazole) was 
used as chromogen and the resultant formaldehyde prod-
ucts was measured at 540 nm (adapted from [39]).
Genotoxicity assay
The genotoxic potential of rGO was evaluated by micro-
nuclei assay in peripheral blood. The assay was per-
formed in accordance with the Redbook 2000: IV.C.1.d 
Mammalian Erythrocyte Micronucleus Test [40]. Briefly, 
after fixation in methanol for 10 min, three good-quality 
smears prepared from each blood sample (n =  3 blood 
samples; total n  =  9 smear slide/time) were left to air-
dry, stained with Leishman solution for 12–15  min and 
then analyzed using an Olympus BX51 photomicroscope 
(Japan) at 400× or 1000× magnification, as required.
From each smear slide, the frequency of micronu-
clei were determined by counting a total of at least 1000 
erythrocytes and expressed as per 1000 cells (%). Since 
the occurrence of possible mutagenesis was not observ-
able at earlier periods of times (15  min, 1 and 3  h), the 
analysis was solely performed in the 7 day-samples.
Histopathological and immunohistochemistry assessment
Immediately after blood collection, the rats were per-
fused with physiological saline followed by 4 % paraform-
aldehyde in 0.1 M PBS, pH 7.4. The brains and peripheral 
organs (liver and kidney) of rGO-injected rats and con-
trols were removed and routinely processed for paraffin 
embedding [41]. Coronal 5  μm thick sections of brain, 
liver and kidney were stained with Hematoxylin-eosin 
for histological evaluation, Masson’s trichrome technique 
to visualize collagen fibers or immunostained using pri-
mary antibodies (see Table  6) using standard protocols. 
Briefly, the endogenous peroxidase activity was quenched 
with 3 % hydrogen peroxide, (two cycles of 10 min) and 
epitope retrieval was accomplished with 10 mM sodium 
citrate buffer, pH 6.0, in a steamer (95–99 °C) for 30 min. 
Non-specific antigen binding was blocked with 5  % 
skimmed milk powder for 1  h. Slides were incubated 
with the primaries antibodies for 16–18 h in a humidified 
chamber at 4  °C. After washing twice with phosphate-
buffered saline (PBS, pH 7.4), the slides were incubated 
with biotinylated anti-rabbit secondary antibody (EnVi-
sion_HRP link, Dako Cytomation, CA, USA) for 30 min 
at room temperature. Color was developed with a diam-
inobenzidine chromogenic solution (DAB+, Dako Cyto-
mation) and nuclei were counterstained with Harry’s 
hematoxylin; after ethanol dehydration slides were 
mounted in Canada balsam. Negative control was done 
by replacing the primary antibody with 1 % PBS-bovine 
Table 6 Primary antibodies used in this study
Antibody Dilution Supplier Reference Application
Caspase 3 1:400 Santa Cruz Sc‑7148 WB
Caspase 9 1:50 Sigma Aldrich C7729 IHC
Catalase 1:400 Santa Cruz sc‑271242 WB
GFAP 1:100 Dako Z0334 IHC
GFAP 1:500 Dako Z0334 WB
IFN‑γ 1:500 Santa Cruz sc‑9344 WB
NeuN 1:500 Merck Millipore ABN78 IHC
NeuN 1:1000 Merck Millipore ABN78 WB
SOD‑1 1:500 Santa Cruz sc‑11407 WB
TNF‑α 1:1000 Cell signaling #11948 WB
β‑Actin 1:1000 Sigma Aldrich A2228 WB
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serum albumin. Images were captured on an Olympus 
BX51 photomicroscope (Japan).
Western blotting
Western blotting was performed in hippocampal 
homogenates (n = 5 for each time, including single con-
trol) as previously described [12]. After electrotrans-
fer, the membranes were incubated with 5  % skimmed 
milk powder to block non-specific sites prior followed 
by washing with TBS-T (0.1 % Tris-buffered saline with 
0.05 % Tween 20, pH 7.4). Subsequently, the membranes 
were incubated with primary antibodies (see Table  6). 
Then, the membrane were washed with TBS-T and incu-
bated with HRP-labeled anti-mouse (for anti-catalase 
and anti-β-actin), anti-goat (for anti-IFN-γ) or anti-rabbit 
(anti-caspase 3, SOD-1, anti-GFAP, anti-NeuN and anti-
TNF-α) secondary antibody (1:1000, Sigma Aldrich). 
Bands were visualized using a chemiluminescence kit 
(Super Signal West Pico Chemiluminescent Substrate; 
Pierce Biotechnology, Rockford, IL, USA) according to 
the manufacturer’s instructions. The luminescent sig-
nal from bands was captured by a G:BoxiChemi camera 
(Syngene, Cambridge, UK) and band intensities were 
quantified using Image J 1.45S (NIH, Bethesda, MD, 
USA). Blots were stripped and reprobed for β-actin to 
monitor protein loading the efficiency of blot transfer, 
and non-specific changes in protein levels.
Statistical analysis
One-way ANOVA followed by Bonferroni post hoc test 
was performed for multiple variant analyses. Differences 
were considered statistically significant at p  <  0.05. All 
values were expressed as the mean ±  standard error of 
the mean (SEM). All analyses were done using Prism 
software, version 5 (GraphPad Inc., La Jolla, CA, USA).
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